Mifepristone (RU 486) Compared with High-Dose Estrogen and Progestogen for Emergency Postcoital Contraception

New England Journal of Medicine

Volumn 327, Issue 15, 1992, Pages 1041-1044

  Glasier, Anna ^a,b   Thong, K J ^a   Dewar, Maria ^a   Mackie, May ^b   Baird, David T ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b NHS LOTHIAN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETHINYLESTRADIOL; MIFEPRISTONE; NORGESTREL; POSTCOITUS CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTRACEPTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; EMERGENCY; FEMALE; HEADACHE; HORMONE URINE LEVEL; HUMAN; MAJOR CLINICAL STUDY; MENSTRUATION DISORDER; NAUSEA; PREGNANCY; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 0026761586     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199210083271501     Document Type: Article

References (22)

1. Fleissig A. Unintended pregnancies and the use of contraception: changes from 1984 to 1989. BMJ 1991; 302: 147.
2. Yuzpe AA, Lancee WJ. Ethinylestradiol and dl-norgestrel as a postcoital contraceptive. Fertil Steril 1977; 28: 932–6.
3. Fasoli M, Parazzini F, Cecchetti G, La Vecchia C. Post-coital contraception: an overview of published studies. Contraception 1989; 39: 459–68.
4. [Erratum, Contraception 1989; 39: 699.]
5. Rowlands S, Guillebaud J, Bounds N, Booth M. Side effects of danazol compared with an ethinyloestradiol/norgestrel combination when used for postcoital contraception. Contraception 1983; 27: 39–49.
6. Task Force on Post-ovulatory Methods for Fertility Regulation. Postcoital contraception with levonorgestrel during the peri-ovulatory phase of the menstrual cycle. Contraception 1987; 36: 275–86.
7. Herrmann W, Wyss R, Riondel A, et al. Effet d'un stéroide anti-progestérone chez la femme: interruption du cycle menstruel et de la grossesse au début. C R Acad Sci III 1982; 294: 933–8.
8. Rodger MW, Baird DT. Induction of therapeutic abortion in early pregnancy with mifepristone in combination with prostaglandin pessary. Lancet 1987; 2: 1415–8.
9. Van Look PFA, Bygdeman M. Antiprogestational steroids: a new dimension in human fertility regulation. Oxf Rev Reprod Biol 1989; 11: 2–60.
10. Silvestre L, Dubois C, Renault M, Rezvani Y, Baulieu E-E, Ulmann A. Voluntary interruption of pregnancy with mifepristone (RU 486) and a prostaglandin analogue: a large-scale French experience. N Engl J Med 1990; 322: 645–8.
11. Luukkainen T, Heikinheimo O, Haukkamaa M, Låhteenmåki P. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486. Fertil Steril 1988; 49: 961–3.
12. Liu JH, Garzo G, Morris S, Stuenkel C, Ulmann A, Yen SSC. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486. J Clin Endocrinol Metab 1987; 65: 1135–40.
13. Swahn M-L, Bygdeman M, Cekan S, Xing S, Masironi B, Johannisson E. The effect of RU 486 administered during the early luteal phase on bleeding pattern, hormonal parameters and endometrium. Hum Reprod 1990; 5: 402–8.
14. Frydman R, Baton C, Lelaidier C, Vial M, Bourget P, Fernandez H. Mifepristone for induction of labour. Lancet 1991; 337: 488–9.
15. Hodgen GD. Antiprogestins: the political chemistry of RU486. Fertil Steril 1991; 56: 394–5.
16. Glasier A, Thong KJ, Dewar M, Mackie M, Baird DT. Postcoital contraception with mifepristone. Lancet 1991; 337: 1414–5.
17. Yong E-L, Glasier A, Hillier H, et al. Effect of cyclofenil on hormonal dynamics, follicular development and cervical mucus in normal and oligomenorrhoeic women. Hum Reprod 1992; 7: 39–43.
18. Ratcliffe WA, Corrie JET, Dalziel AH, Macpherson JS. Direct 125I-radio-ligand assays for serum progesterone compared with assays involving extraction of serum. Clin Chem 1982; 28: 1314–8.
19. Silvestre L, Bouali Y, Ulmann A. Postcoital contraception: myth or reality? Lancet 1991; 338: 39–41.
20. Dixon GW, Schlesselman JJ, Ory HW, Blye RP. Ethinyl estradiol and conjugated estrogens as postcoital contraceptives. JAMA 1980; 244: 1336–9.
21. Nieman LK, Choate TM, Chrousos GP, et al. The progesterone antagonist RU 486: a potential new contraceptive agent. N Engl J Med 1987; 316: 187–91.
22. Garzo VG, Liu J, Ulmann A, Baulieu E, Yen SSC. Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle. J Clin Endocrinol Metab 1988; 66: 508–17.